146 related articles for article (PubMed ID: 11479851)
1. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.
Soffer SZ; Moore JT; Kim E; Huang J; Yokoi A; Manley C; O'Toole K; Stolar C; Middlesworth W; Yamashiro DJ; Kandel JJ
J Pediatr Surg; 2001 Aug; 36(8):1177-81. PubMed ID: 11479851
[TBL] [Abstract][Full Text] [Related]
2. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor.
Soffer SZ; Kim E; Moore JT; Huang J; Yokoi A; Manley C; O'Toole K; Middlesworth W; Stolar C; Yamashiro D; Kandel J
J Pediatr Surg; 2001 Dec; 36(12):1781-4. PubMed ID: 11733906
[TBL] [Abstract][Full Text] [Related]
3. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
[TBL] [Abstract][Full Text] [Related]
4. All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor.
Kim E; Moore J; Huang J; Soffer S; Manley CA; O'Toole K; Middlesworth W; Stolar CJ; Kandel JJ; Yamashiro DJ
J Pediatr Surg; 2001 Feb; 36(2):287-90. PubMed ID: 11172417
[TBL] [Abstract][Full Text] [Related]
5. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.
Frischer JS; Huang J; Serur A; Kadenhe-Chiweshe A; McCrudden KW; O'Toole K; Holash J; Yancopoulos GD; Yamashiro DJ; Kandel JJ
Int J Oncol; 2004 Sep; 25(3):549-53. PubMed ID: 15289855
[TBL] [Abstract][Full Text] [Related]
6. Suppression of primary tumor growth in a mouse model of human neuroblastoma.
Rowe DH; Huang J; Li J; Manley C; O'Toole KM; Stolar CJ; Yamashiro DJ; Kandel JJ
J Pediatr Surg; 2000 Jun; 35(6):977-81. PubMed ID: 10873048
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
9. Distinct response of experimental neuroblastoma to combination antiangiogenic strategies.
Kim ES; Soffer SZ; Huang J; McCrudden KW; Yokoi A; Manley CA; Middlesworth W; Kandel JJ; Yamashiro DJ
J Pediatr Surg; 2002 Mar; 37(3):518-22. PubMed ID: 11877680
[TBL] [Abstract][Full Text] [Related]
10. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
[TBL] [Abstract][Full Text] [Related]
11. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
Borgström P; Gold DP; Hillan KJ; Ferrara N
Anticancer Res; 1999; 19(5B):4203-14. PubMed ID: 10628376
[TBL] [Abstract][Full Text] [Related]
12. Wilms' tumor growth is suppressed by antiangiogenic pigment epithelium-derived factor in a xenograft model.
Abramson LP; Stellmach V; Doll JA; Cornwell M; Arensman RM; Crawford SE
J Pediatr Surg; 2003 Mar; 38(3):336-42; discussion 336-42. PubMed ID: 12632345
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth.
Ghosh S; Maity P
Int Immunopharmacol; 2006 Oct; 6(10):1550-9. PubMed ID: 16919827
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
[TBL] [Abstract][Full Text] [Related]
15. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
17. Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors.
Huang J; Moore J; Soffer S; Kim E; Rowe D; Manley CA; O'Toole K; Middlesworth W; Stolar C; Yamashiro D; Kandel J
J Pediatr Surg; 2001 Feb; 36(2):357-61. PubMed ID: 11172434
[TBL] [Abstract][Full Text] [Related]
18. A murine vascular endothelial growth factor antibody inhibits in vivo growth of human Caki-I renal adenocarcinoma.
Dagnaes-Hansen F; Rasmussen LM; Tilton R; Denner L; Flyvbjerg A
Anticancer Res; 2003; 23(2B):1625-30. PubMed ID: 12820432
[TBL] [Abstract][Full Text] [Related]
19. Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice.
Bauer TW; Fan F; Liu W; Camp ER; Yang A; Somcio RJ; Bucana CD; Singh R; Ellis LM
Ann Surg Oncol; 2007 Oct; 14(10):2838-46. PubMed ID: 17653802
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
